BP1002

About Bio-Path Holdings

Bio-Path Holdings is an oncology-focused biotech developing non-toxic, targeted cancer therapies for fragile patients ineligible for standard chemotherapy. Its core innovation is the DNAbilize® liposomal delivery platform, designed to concentrate antisense drugs at the tumor site while sparing healthy tissue. The company's strategy centers on advancing its lead asset, prexigebersen, in AML while exploring its platform's utility in solid tumors and other blood cancers through earlier-stage candidates. Recent leadership changes aim to revitalize clinical progress and corporate strategy.

About Bio-Path Holdings

Bio-Path Holdings is an oncology-focused biotech developing non-toxic, targeted cancer therapies for fragile patients ineligible for standard chemotherapy. Its core innovation is the DNAbilize® liposomal delivery platform, designed to concentrate antisense drugs at the tumor site while sparing healthy tissue. The company's strategy centers on advancing its lead asset, prexigebersen, in AML while exploring its platform's utility in solid tumors and other blood cancers through earlier-stage candidates. Recent leadership changes aim to revitalize clinical progress and corporate strategy.

Therapeutic Areas